- Home
- BIRK vs XENE Comparison
BIRK vs XENE Comparison
Compare BIRK & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BIRK | XENE |
|---|---|---|
| Founded | 1774 | 1996 |
| Country | United Kingdom | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.7B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BIRK | XENE |
|---|---|---|
| Price | $30.01 | $56.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $61.43 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 2.4M | 602.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | $13.71 | N/A |
| Revenue Next Year | $14.30 | $2,496.48 |
| P/E Ratio | $17.48 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.25 | $35.67 |
| 52 Week High | $50.73 | $72.66 |
Technical Indicators
Market Signals| Indicator | BIRK | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 28.97 | 36.75 |
| Support Level | N/A | $52.40 |
| Resistance Level | $37.29 | $59.43 |
| Average True Range (ATR) | 1.18 | 1.86 |
| MACD | -0.24 | -0.21 |
| Stochastic Oscillator | 6.08 | 2.79 |
Price Performance
Historical ComparisonAbout BIRK Birkenstock Holding plc
Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.